Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration With Gates Institute At University Of Colorado Anschutz Medical Campus
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers
Charles River Laboratories International, Inc. (NYSE:CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.